GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » ROA %
中文

Bruker (Bruker) ROA %

: 20.37% (As of Dec. 2023)
View and export this data going back to 2000. Start your Free Trial

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Bruker's annualized Net Income for the quarter that ended in Dec. 2023 was $822 Mil. Bruker's average Total Assets over the quarter that ended in Dec. 2023 was $4,035 Mil. Therefore, Bruker's annualized ROA % for the quarter that ended in Dec. 2023 was 20.37%.

The historical rank and industry rank for Bruker's ROA % or its related term are showing as below:

BRKR' s ROA % Range Over the Past 10 Years
Min: 2.94   Med: 8.11   Max: 11.07
Current: 11.07

During the past 13 years, Bruker's highest ROA % was 11.07%. The lowest was 2.94%. And the median was 8.11%.

BRKR's ROA % is ranked better than
88.79% of 865 companies
in the Medical Devices & Instruments industry
Industry Median: -1.69 vs BRKR: 11.07

Bruker ROA % Historical Data

The historical data trend for Bruker's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.05 5.42 8.27 8.17 10.87

Bruker Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.21 8.30 5.99 9.18 20.37

Competitive Comparison

For the Medical Devices subindustry, Bruker's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bruker ROA % Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Bruker's ROA % distribution charts can be found below:

* The bar in red indicates where Bruker's ROA % falls into.



Bruker ROA % Calculation

Bruker's annualized ROA % for the fiscal year that ended in Dec. 2023 is calculated as:

ROA %=Net Income (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=427.2/( (3611.8+4249.9)/ 2 )
=427.2/3930.85
=10.87 %

Bruker's annualized ROA % for the quarter that ended in Dec. 2023 is calculated as:

ROA %=Net Income (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=822/( (3819.6+4249.9)/ 2 )
=822/4034.75
=20.37 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data. ROA % is displayed in the 30-year financial page.


Bruker  (NAS:BRKR) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=822/4034.75
=(Net Income / Revenue)*(Revenue / Total Assets)
=(822 / 3418)*(3418 / 4034.75)
=Net Margin %*Asset Turnover
=24.05 %*0.8471
=20.37 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Bruker ROA % Related Terms

Thank you for viewing the detailed overview of Bruker's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


Bruker (Bruker) Business Description

Traded in Other Exchanges
Address
40 Manning Road, Billerica, MA, USA, 01821
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.
Executives
Frank H Laukien director, 10 percent owner, officer: CEO, President C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer director 9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma director C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch officer: Pres. Bruker Nano Inc. BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega officer: Group President Bruker CALID BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause officer: Pres. & CEO, Bruker EST BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson director 6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean director BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse officer: President, BioSpin Group 40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman officer: Vice President, Corp Contr. 55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss director 395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins director C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139